NCI-CCC Lymphoma Tumor Board Question

Questions discussed in this category

How would you manage LPL with associated AL amyloidosis?

Bendamustine or Cy-Bor-D? Or another induction regimen? Would you consider autologous transplant in CR1 like you would for AL amyloid on its own or wi...

1 Answer available

How would you manage a patient with primary CNS lymphoma who received R-MTX followed by autologous transplant with systemic relapse 5 years later for which R-Pola-CHP was given now followed by CNS relapse?

Pt not interested in another auto transplant, but willing to consider other consolidation. Systemic DLBCL appears morphologically similar to the CNS r...

1 Answer available

What is your approach to managing follicular lymphoma with central nervous system involvement?

Have you treated such cases with systemic therapies? If so, which ones (e.g., cytotoxic chemotherapy, anti-CD20 monoclonal antibodies, or targeted age...

1 Answer available

What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?

1 Answer available

How would you manage a patient with marginal zone lymphoma who progress after treatment on a BKTI?

1 Answer available

How do you approach patients with AL amyloidosis with t(11;14) who have not achieved a hematologic complete response to induction therapy with 6 cycles of Dara-CyBorD?

Specifically, in the setting of patients that have had a PR or VGPR and are not actively progressing.

2 Answers available

For a patient with ENKTL nasal type (nose/sinus involvement) who has hepatic toxicity with pegasparaginase but a CR after 2 cycles of chemotherapy with a plan for "sandwich" radiotherapy - what, if any, chemotherapy would you resume after completion of radiation?

I am not sure there is much efficacy for a regimen that does not include asparaginase. The patient received 2 cycles of P-GemOx, then was admitted for...

2 Answers available

How would you consolidate a patient with primary refractory double hit lymphoma with secondary CNS involvement?

At the time of initial diagnosis, there was no clear CNS involvement. When it became clinically apparent disease was refractory to EPOCH, there was CS...

2 Answers available

How would you treat an elderly patient with Stage IIA cHL with 3 nodal sites of involvement who has a contraindication to bleomycin?

DLCO 65% that is of unclear etiology but not due to disease and no cardiac or pulmonary functional limitations.

1 Answer available

How would you treat an elderly newly diagnosed tDLBCL that has previously seen R-CHOP and Bendamustine-Obinutuzumab prior to the transformative event?

7 Answers available

What chemotherapy regimen would you offer to a patient with DLBCL who was originally diagnosed and treated (R-CHOP) 15 years ago, now with a 2nd primary/late recurrence of DLBCL?

1 Answer available

How would you treat an elderly male with history of mantle cell lymphoma who relapsed after chemoimmunotherapy and cBTKi w/ multiple co-morbidities including CKD and CHF w/ low EF?

1 Answer available

How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?

1 Answer available

How would you treat a patient who received 2 cycles of R-CHOP for DLBCL who was subsequently diagnosed with follicular lymphoma?

Would you continue R-CHOP or would you switch therapy?

1 Answer available

How would you treat an older patient with B symptoms and biopsy consistent with grade 3 follicular lymphoma but noted to have a PET scan with SUV readings of > 20?

1 Answer available

How would you manage a case of subcutaneous panniculitis-like T cell lymphoma (A/B) who is already on steroids and methotrexate for autoimmune disease?

1 Answer available

How would you manage biopsy-proven DLBCL in a patient who was treated with 6 cycles of R-CHOP 15 years ago for DLBCL?

Would you consider this de novo DLBCL (unable to assess for clonality)? How would you handle prior anthracycline exposure?

1 Answer available

How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?

2 Answers available

How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?

2 Answers available

What is your preferred third-line therapy for a fit patient with symptomatic, relapsed follicular lymphoma who has failed bendamustine-rituximab and lenalidomide-rituximab?

2 Answers available

How would you manage a patient with NLPHL and CKD who relapsed after a long disease free interval (i.e. 7 years) following bendamustine?

1 Answer available

What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?

1 Answer available

How would you treat a BTKi naive p53 mutated MCL in 1st relapse with disease noted both systemically and in the CNS?

1 Answer available

How would you approach treatment for a R/R mantle cell lymphoma patient with a history of autoimmune hepatitis who has progressed on both a covalent and non-covalent BTKi?

1 Answer available

How would you approach therapy for a patient with newly diagnosed non-GC DLBCL with previous anthracycline exposure?

240-300 mg/m2 prior exposure. How would your management change in young fit/older individuals with comorbidities? Would you obtain interval TTE during...

2 Answers available

How would you approach therapy for a patient with symptomatic secondary CNS marginal zone lymphoma, but with low-volume systemic disease that would otherwise not warrant therapy?

Would your approach differ for a 30 year old and a 70 year old?

3 Answers available

What is your approach to curative-intent therapy for a young, fit patient with newly-diagnosed monomorphic epitheliotropic intestinal T cell lymphoma (MEITL)?

Do you incorporate PEG-asparaginase or brentuximab vedotin (for CD30-expressing malignant cells) into anthracycline-based induction regimens? Do you c...

1 Answer available

In light of the TRIANGLE data at ASH, how should we now approach a transplant-eligible patient with a new diagnosis of aggressive mantle cell lymphoma?

2 Answers available

How would you manage a transplant-eligible patient with DLBCL who relapsed 6-12 months following a CR1 to R-CHOP and then attained a CR2 to platinum-based salvage chemoimmunotherapy?

How do you choose between CAR-T and autoSCT, for example?

3 Answers available

How would you treat a fit patient with a history of relapsed CLL who now presents with Richter transformation s/p autologous anti-CD19 chimeric antigen receptor (CAR) T-cells?

1 Answer available

How would you approach therapy for a transplant-eligible patient with peripheral T cell lymphoma NOS who experiences early relapse after CHOEP, but achieves remission to salvage therapy?

Would you still go to auto or consider allo?

1 Answer available

How would treat a patient with good performance status with PTCL-NOS found to have leptomeningeal disease during treatment course with CHOEP?

Would you intercalate HD-MTX with her CHOEP?

1 Answer available

How would you manage a CLL patient with Richters transformation that is resistant to R-CHOP with transfusion dependent cytopenias and a marrow demonstrating significant involvement by DLBCL and CLL?

2 Answers available

What is your approach in a fit patient, advanced stage, bulky classical Hodgkin lymphoma who has decreased disease burden in areas but a persistent, hypermetabolic (Deauville 5) anterior mediastinal mass following two cycles of AAVD?

2 Answers available

How would you approach therapy for a patient with a history of classical HL who achieved a CR to 6 cycles of Brentuximab plus AVD who now presents with widespread non-GC DLBCL?

2 Answers available

How would you approach therapy for BR-refractory Waldenstrom Macroglobulinemia when there is a mixed response to zanabrutinib?

1 Answer available

What treatment would you recommend in an older patient with multiply relapsed double-hit lymphoma with recurrence following ASCT, pola-BR, and CAR-T therapy?

1 Answer available

How would you treat a patient with blastoid mantle cell lymphoma with hepatic involvement causing significantly elevated bilirubin?

1 Answer available

Would you recommend allogeneic stem cell transplantation for consolidation in a patient with follicular lymphoma who relapsed within 13 months of initial chemo-immunotherapy?

2 Answers available

What is the optimal treatment for a fit, elderly patient with NGC diffuse large B cell lymphoma that recurred about 1 year after dose-attenuated R-CHOP?

1 Answer available

How would you treat gray zone lymphoma which initially achieved a CR after 2 cycles of DA-R-EPOCH, but end-of-treatment PET demonstrates progression with new sites of biopsy-proven disease?

1 Answer available

In light of ALK-directed therapy, what is the role of chemotherapy for patients with newly diagnosed ALK+ DLBCL?

1 Answer available

How do you sequence therapy in an older patient with newly-diagnosed blastoid mantle cell lymphoma with a 17p deletion?

1 Answer available

How would you approach therapy for relapsed/refractory mantle cell lymphoma restricted to the CNS?

1 Answer available

How would you approach therapy for newly diagnosed germinal-center DLBCL who previously received an unknown systemic regimen with radiation for history of Hodgkin Lymphoma?

Would you give R-CHOP without knowing if there was use of prior anthracycline?

1 Answer available

How would you manage an asymptomatic elderly frail patient with newly diagnosed mantle cell lymphoma with TP53 mutation?

Ki67 = 90% with multiple small nodes on PET scan and normal CBC

1 Answer available

How would you manage a patient with history of follicular lymphoma treated with Bendamustine-Rituximab who now has a new FDG avid lesion that is biopsy proven CD30 positive CD20 negative DLBCL?

2 Answers available

What's the optimal management of stage IA nodal ATLL in a young fit patient?

Patient in mid-30s with no major medical history presented with isolated left neck swelling. Incisional biopsy w/ HTLV1/2 associated ATLL, Ki67 of >...

1 Answer available